Leonard M. Reyno

Learn More
PURPOSE To compare the incidence of palliative response in patients with hormone-resistant prostate cancer (HRPC) treated with mitoxantrone and prednisone (MP) plus clodronate with that of patients(More)
OBJECTIVE To define the optimal treatment for women with stage III or locally advanced breast cancer (LABC). EVIDENCE Systematic review of English-language literature retrieved from MEDLINE (1984(More)
PURPOSE This study aimed to (1) develop a population pharmacokinetic model for suramin; (2) use Bayesian methods to assess suramin pharmacokinetics in individual patients; (3) use individual(More)
PURPOSE Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective randomized clinical trial was designed to(More)